Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner.

Area of Science:

• Pharmacology
• Molecular Biology
• Cell Biology

Background:

• Alpha2-adrenoceptors (α2A, α2B, α2C) are crucial targets for various physiological processes.
• Understanding subtype-specific drug interactions is vital for developing targeted therapeutics.
• Existing methods for characterizing adrenoceptor activity can be further refined.

Purpose of the Study:

• To evaluate the efficacy of a GTPase hydrolysis assay for identifying subtype-selective alpha2-adrenoceptor agonists.
• To characterize the agonist activity of dexmedetomidine, UK14,304, and oxymetazoline across different alpha2-adrenoceptor subtypes.
• To validate the GTPase assay findings with complementary cAMP accumulation experiments.

Main Methods:

• Utilized Chinese hamster ovary (CHO) cells transfected with human alpha2A-, alpha2B-, and alpha2C-adrenoceptor subtypes.
• Measured alpha2-adrenoceptor-stimulated GTP hydrolysis in response to various agonists.
• Performed cAMP accumulation assays on cell lines endogenously expressing alpha2A (HEL) and alpha2B (NG108-15) subtypes.

Main Results:

• (-)-Adrenaline stimulated pertussis toxin-sensitive GTPase activity significantly across all subtypes, with varying potencies.
• Dexmedetomidine acted as a full agonist at α2B and partial agonist at α2A/α2C subtypes.
• UK14,304 was a full agonist at α2A and partial agonist at α2B/α2C, while oxymetazoline showed partial agonism at α2B only.

Conclusions:

• The GTPase hydrolysis assay effectively differentiates the activity of alpha2-adrenoceptor agonists at specific subtypes.
• This assay serves as a valuable tool for the discovery and characterization of novel, subtype-selective alpha2-adrenoceptor modulators.
• Findings align with cAMP accumulation data, reinforcing the assay's utility in adrenoceptor research.